Patents by Inventor Michael Eissenstat

Michael Eissenstat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting cytochrome P450
    Patent number: 9849107
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: December 26, 2017
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan
  • Compositions and methods for inhibiting cytochrome P450 2D6
    Patent number: 9604952
    Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 28, 2017
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
  • Diamide inhibitors of cytochrome P450
    Patent number: 9540354
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 10, 2017
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan
  • COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450
    Publication number: 20160361287
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 15, 2016
    Inventors: Michael EISSENSTAT, Dehui DUAN
  • Benzofuran-containing amino acid inhibitors of cytochrome P450
    Patent number: 9403789
    Abstract: Benzofuran-containing amino acid compounds are provided that are potent inhibitors of cytochrome P450 (CYP) enzymes. The compounds have the general structure where at least one of R1, R2, R3, R4, R5, and R6 is —S(O)n—(CH2)0-3-(benzofuranyl), —(CH2)1-5—N(R)(—SO2-benzofuranyl), —C(O)n—(CH2)0-3-(benzofuranyl), —(CH2)1-5—N(R)(C(?O)-(benzofuranyl), or C1-C6 alkylene-(benzofuranyl). Pharmaceutical compositions containing the inhibitors are provided and these compositions can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: August 2, 2016
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan, Jihye Kang
  • Compositions and methods for inhibiting cytochrome P450
    Patent number: 9233952
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: January 12, 2016
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • METHODS FOR INHIBITING DRUG DEGRADATION
    Publication number: 20150284352
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: February 9, 2015
    Publication date: October 8, 2015
    Inventors: Michael EISSENSTAT, Dehui DUAN, Sergei GULNIK, John W. Erickson
  • Diamide Inhibitors of Cytochrome P450
    Publication number: 20150087676
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: December 9, 2014
    Publication date: March 26, 2015
    Inventors: Michael Eissenstat, Dehui Duan
  • Methods for inhibiting drug degradation
    Patent number: 8952056
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: February 10, 2015
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
  • Diamide inhibitors of cytochrome P450
    Patent number: 8906647
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: December 9, 2014
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6
    Publication number: 20140343078
    Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 20, 2014
    Inventors: Michael EISSENSTAT, Dehui DUAN, Ji-Hye KANG
  • 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
    Patent number: 8791157
    Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: July 29, 2014
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
  • HCV protease inhibitors
    Patent number: 8765667
    Abstract: Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: July 1, 2014
    Inventors: Michael Eissenstat, Rongjian Lu, Sang Uk Kang
  • Bimacrocylic HCV NS3 protease inhibitors
    Patent number: 8703700
    Abstract: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: April 22, 2014
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Pavel Majer, Michael Eissenstat, Rongjuan Lu
  • HIV protease inhibitor and cytochrome p450 inhibitor combinations
    Patent number: 8673970
    Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: March 18, 2014
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
  • COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450
    Publication number: 20140024671
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 23, 2014
    Inventors: Michael EISSENSTAT, Dehui DUAN
  • 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
    Patent number: 8569364
    Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: October 29, 2013
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
  • Compositions and methods for inhibiting cytochrome P450
    Patent number: 8481520
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: July 9, 2013
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • Benzofuran derived HIV protease inhibitors
    Patent number: 8389571
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: March 5, 2013
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventor: Michael Eissenstat
  • Bimacrocylic HCV NS3 Protease Inhibitors
    Publication number: 20120141414
    Abstract: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.
    Type: Application
    Filed: May 24, 2010
    Publication date: June 7, 2012
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: Pavel Majer, Michael Eissenstat, Rongjuan Lu